Discovery of cell-internalizing artificial nucleic acid aptamers for lung fibroblasts and targeted drug delivery.


Journal

Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703

Informations de publication

Date de publication:
12 2020
Historique:
received: 01 09 2020
accepted: 24 09 2020
pubmed: 20 10 2020
medline: 20 3 2021
entrez: 19 10 2020
Statut: ppublish

Résumé

Lung fibroblasts play major roles in the lung repair/fibrosis process through synthesis and remodeling of extracellular matrix. Those aberrant activations and elevated proliferations are associated with several fibrotic lung diseases, such as idiopathic pulmonary fibrosis (IPF). Targeting fibroblasts is a promising approach for preventing aberrant remodeling of lung architecture and protect irreversible pulmonary fibrosis. In this study, we developed an aptamer that can target lung fibroblasts and explored its potential as a delivery vehicle of cytotoxic agents intracellularly. The aptamer was discovered from artificial nucleic acid libraries through cell-based systematic evolution of ligands by exponential enrichment (cell-SELEX). This indole-modified aptamer can bind to LL97A cells, a fibroblast cell line derived from IPF patients, with high affinity (K

Identifiants

pubmed: 33074117
pii: S0045-2068(20)31619-9
doi: 10.1016/j.bioorg.2020.104321
pii:
doi:

Substances chimiques

Aptamers, Nucleotide 0
Drug Carriers 0
Indoles 0
Ligands 0
Nucleic Acids 0
Oligopeptides 0
monomethylauristatin F 0
indole 8724FJW4M5
DNA 9007-49-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104321

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Hiro Uemachi (H)

Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan; National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka 567-0085, Japan; DSP Cancer Institute, Sumitomo Dainippon Pharma Co., Ltd., Osaka 554-0022, Japan.

Yuuya Kasahara (Y)

Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan; National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka 567-0085, Japan. Electronic address: y-kasahara@nibiohn.go.jp.

Keisuke Tanaka (K)

Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan; National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka 567-0085, Japan.

Takumi Okuda (T)

Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan; National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka 567-0085, Japan.

Yoshihiro Yoneda (Y)

National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka 567-0085, Japan.

Satoshi Obika (S)

Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan; National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka 567-0085, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH